Referred to the House Committee on Energy and Commerce.
The bill adds a new NIH program called the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project to fund and coordinate research, training, and investigation related to Down syndrome. It directs NIH to support high‑risk research, lifespan cohort studies, inclusive clinical trials, biomarker and mechanism studies, research on co-occurring conditions (for example Alzheimer’s and autoimmunity), and quality‑of‑life research; requires coordination across NIH, stakeholder consultation, and biennial reports to Congress cataloging activities and real‑world evidence.
Funding uncertainty fuels most disagreement
Relative to its intended legislative type, this bill clearly creates statutory authority for an NIH program on Down syndrome and outlines substantive research priorities, coordination, stakeholder consultation, and reporting requirements.
The bill adds a new NIH program called the INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project to fund and coordinate research, training, and investigation related to Down syndrome.
It directs NIH to support high‑risk research, lifespan cohort studies, inclusive clinical trials, biomarker and mechanism studies, research on co-occurring conditions (for example Alzheimer’s and autoimmunity), and quality‑of‑life research; requires coordination across NIH, stakeholder consultation, and biennial reports to Congress cataloging activities and real‑world evidence.
Substantively modest authorization with low controversy improves prospects, but requires appropriation and floor/committee scheduling to enact.
Relative to its intended legislative type, this bill clearly creates statutory authority for an NIH program on Down syndrome and outlines substantive research priorities, coordination, stakeholder consultation, and reporting requirements. It stops short of providing detailed implementation mechanisms or funding instructions that would be expected to fully operationalize and resource the program it authorizes.
Funding uncertainty fuels most disagreement
These are examples from the analysis, not a ranked list of the most-affected groups.
Funding uncertainty fuels most disagreement
Likely to strongly support the bill as advancing health equity and disability‑inclusive research, improving diagnosis and treatment, and centering people with Down syndrome.
Would welcome stakeholder consultation and lifespan focus but push for explicit funding, supports for families, and safeguards against misuse of genetic data.
Generally supportive because it coordinates research, promotes inclusive trials, and increases reporting to Congress.
Will seek clarity on funding, measurable outcomes, and explicit steps to avoid duplication with existing NIH work.
May cautiously support research to improve health and quality of life for people with Down syndrome, but worries about expanded federal programs, new spending without offsets, and potential ethical concerns from genetic research.
Would prefer narrower scope and clear cost constraints.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantively modest authorization with low controversy improves prospects, but requires appropriation and floor/committee scheduling to enact.
The bill has not accumulated any surfaced votes yet.
Funding uncertainty fuels most disagreement
Substantively modest authorization with low controversy improves prospects, but requires appropriation and floor/committee scheduling to en…
Relative to its intended legislative type, this bill clearly creates statutory authority for an NIH program on Down syndrome and outlines substantive research priorities, coordination, stakeholder consultation, and repo…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.